Literature DB >> 8969539

Alcohol consumption and seroconversion from hepatitis B e antigen in the Okinawa Japanese.

H Nomura1, J Hayashi, W Kajiyama, S Kashiwagi.   

Abstract

A total of 1,113 hepatitis B surface antigen (HBsAg) carriers of Yaeyama District in Okinawa, Japan, were investigated in attempts to elucidate effects of alcohol consumption on seroconversion from hepatitis B e antigen (HBeAg). All of HBsAg carriers were tested for HBeAg. The subjects over 20 years of age were asked about their habitual intake of alcohol and were ranked into three categories: nondrinkers, light drinkers (1-59 g/day), and heavy drinkers (> or = 60 g/day). The prevalence of HBeAg decreased with advancing age and did not differ between the sexes. Logistic regression analyses of the data revealed prevalence curves of HBeAg, depending on the age of subjects. The prevalence curves tended to be higher and decrease more slowly in heavy drinkers than in the nondrinkers. Thus, the possibility that heavy alcohol drinking prolongs seroconversion from HBeAg seems worthy of further consideration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969539

Source DB:  PubMed          Journal:  Fukuoka Igaku Zasshi        ISSN: 0016-254X


  3 in total

Review 1.  Management of alcohol misuse in patients with liver diseases.

Authors:  Jennifer L Peng; Milan Prakash Patel; Breann McGee; Tiebing Liang; Kristina Chandler; Sucharat Tayarachakul; Sean O'Connor; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-12-09       Impact factor: 2.895

Review 2.  Effects of alcohol consumption on viral hepatitis B and C.

Authors:  Hong-Qin Xu; Chun-Guang Wang; Qiang Zhou; Yan-Hang Gao
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

3.  Effect of alcohol on clinical complications of hepatitis virus-induced liver cirrhosis: a consecutive ten-year study.

Authors:  Kodjo-Kunale Abassa; Xiao-Ying Wu; Xiu-Ping Xiao; Hao-Xiong Zhou; Yun-Wei Guo; Bin Wu
Journal:  BMC Gastroenterol       Date:  2022-03-19       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.